Expert Panel to Discuss Growing Global Impact and Innovative New Solutions to Emerging Diseases
April 11 2005 - 2:07PM
PR Newswire (US)
Expert Panel to Discuss Growing Global Impact and Innovative New
Solutions to Emerging Diseases Breakfast Sponsored by Bioaccelerate
Holdings Inc. to be Held at Milken Institute Global Conference NEW
YORK, April 11 /PRNewswire-FirstCall/ -- Bioaccelerate Holdings
Inc. (OTC:BACL) (BULLETIN BOARD: BACL) announced today a
distinguished panel of experts to discuss the global impact and
innovative new solutions to the treatment of neglected diseases at
its Company-sponsored breakfast meeting at the Milken Institute
Global Conference. The invitation-only breakfast will take place on
April 19, 2005, from 6:45 a.m. to 7:45 a.m. in the Brighton Room in
the Executive Center of the Beverly Hilton Hotel in Los Angeles,
CA. "Infectious diseases pose an urgent global crisis-threatening
the economic survival of the poorest countries and the growth and
development of many more," stated Bruce Murdoch, Acting Chief
Executive Officer of Candid Pharmaceuticals, a Bioaccelerate
subsidiary focused on emerging diseases. "Broad-based efforts by
organizations like the World Health Organization (WHO) should be
commended and supported through international effort by
governments, academic institutions and the healthcare industry."
"Since the 1970s, at least 30 new infectious diseases have emerged
for which effective treatments either do not exist or do not always
find their ways to patients. Studies on the effect of AIDS, malaria
and tuberculosis indicate that the social structures and
functioning of societies increasingly affected by these diseases
are being systematically eroded," commented Frank Armstrong, M.D.,
Chief Operating Officer of Bioaccelerate. "The very concept of
sustainable global economic growth may be at stake. For that
reason, this panel topic strongly echoes other key themes that will
be discussed throughout the conference-health, security, trade and
globalization." The panelists include: * Greg Simon, President,
FasterCures / The Center for Accelerating Medical Solutions Mr.
Simon will moderate this breakfast panel, highlighting the urgent
need for a more focused US and international policy and action plan
for dealing with the dire economic impact and immeasurable human
toll from the uncontrolled spread of deadly infectious diseases.
Mr. Simon will discuss how, increasingly, epidemics such as SARS
have emerged as one of greatest risk factors threatening the
stability of an interdependent international economic community and
how global companies need to address this threat within their
strategic business decisions. Prior to joining FasterCures in July
2003, Mr. Simon was CEO of Simon Strategies/Mindbeam, a consulting
firm focusing on clients in biotechnology, health care, technology
and information technology among other issues. From 1993 to 1997,
he was Chief Domestic Policy Advisor to Vice President Al Gore
specifically on economic, science and technology issues. In that
capacity, he oversaw a number of initiatives, including the
programs of the National Institutes of Health, National Cancer
Institute, Food and Drug Administration (FDA), the Human Genome
Project, and the development of the regulatory framework for
biotechnology products. * Michael J. Ryan, MD, MPH, MFPHM,
Coordinator of WHO's Global Alert and Response Unit Dr. Ryan will
provide a "view from the front line" in fighting emerging diseases.
His remarks will focus on how the WHO is working with partners to
put into place an effective global alert and response system, the
need for an investment in building national capacities to detect
and respond to these threats and what the private sector can do it
terms of product development and corporate support. This
presentation will draw deeply from his experiences in dealing with
over 50 international responses over the past three years. Dr. Ryan
has worked with WHO since 1996, when WHO established a unit to
respond to emerging and epidemic disease threats. During his time
at WHO, Dr. Ryan has led numerous outbreak response teams to the
field for diseases such as Ebola, meningitis, cholera, bacillary
dysentery, Crimean-Congo hemorrhagic fever, rift valley fever and
relapsing fever. He became Coordinator of WHO's Global Alert and
Response Team in 2001 and has put into place WHO's epidemic
intelligence, verification and response mechanisms, as well as the
Global Outbreak Alert and Response Network (GOARN), which have been
utilized in recent outbreaks such as SARS and Influenza. He was
appointed Director of Alert and Response Operations in June 2004
with responsibility for the further development and implementation
of the WHO-wide response to epidemics and other public health
emergencies of international concern requiring immediate
operational response and has WHO's Strategic Health Operations
Centre under his responsibility. He completed Medical Training at
University College Galway and his Masters in Public Health at
University College Dublin followed by specialist training in public
health/communicable disease at the UK Communicable Disease
Surveillance Centre in London. * Frank Armstrong, M.D., Chief
Operating Officer, Bioaccelerate Dr. Armstrong will discuss how
Bioaccelerate's business model helps streamline the process of
developing a drugs for a variety of diseases, including infectious
diseases, and bringing needed treatments to millions of people
worldwide. Dr. Armstrong joined Bioaccelerate in January 2005.
Previously, he was CEO of Provensis, a BTG Company, and CEO of
Phoqus, a private drug delivery company. Earlier, he was Head of
Worldwide Product Development for Bayer AG, and Senior Vice
President Medical Research and Communications Group, Zeneca
Pharmaceuticals (now AstraZeneca), based in the US. Dr. Armstrong
holds degrees from the University of Edinburgh in Biochemistry and
Medicine and is a Fellow of the Royal College of Physicians
(Edinburgh) and a Fellow of the Faculty of Pharmaceutical Medicine
in the UK. ABOUT THE WORLD HEALTH ORGANIZATION The WHO is the
United Nations specialized agency for health. It was established on
7 April 1948. WHO's objective, as set out in its Constitution, is
the attainment by all peoples of the highest possible level of
health. Health is defined in WHO's Constitution as a state of
complete physical, mental and social well being and not merely the
absence of disease or infirmity. Additional information on The
World Health Organization is available at http://www.who.org/.
ABOUT FASTERCURES / THE CENTER FOR ACCELERATING MEDICAL SOLUTIONS
FasterCures is an "action tank" committed to building faster tracks
to find tomorrow's cures today. Its mission is to clear the path
between an idea for treatment and getting a treatment to the
patient. Additional information is available at
http://www.fastercures.org/. ABOUT THE MILKEN INSTITUTE GLOBAL
CONFERENCE This year's conference, "Building a Prosperous Future,"
will examine such issues as biotechnology and the promise of
medical breakthroughs; the global investment climate; and the
latest economic developments in Europe, Asia, Latin America and the
US. Among confirmed speakers at the conference are former Vice
President Al Gore; Rupert Murdoch, Chairman and CEO, News
Corporation; Terry Semel, Chairman and CEO, Yahoo!; Charlene
Barshefsky, former U.S. Trade Representative; Mel Karmazin, CEO,
SIRIUS Satellite Radio; Steve Forbes, President and CEO, Forbes;
William Haseltine, former CEO, Human Genome Sciences; Jonathan
Miller, Chairman and CEO, AOL; Mike Milken, Chairman of FasterCures
and the Milken Institute; Steve Wynn, President and CEO, Wynn
Resorts; Sam Zell, Chairman, Equity Group Investments; and more
than 300 others. For complete information about the 2005 Global
Conference, go to: http://www.milkeninstitute.org/gc2005. ABOUT
BIOACCELERATE HOLDINGS INC. Bioaccelerate Holdings Inc. (BACL.OB)
is a pharmaceutical development organization ("PDO"). It conducts
its business directly and through its subsidiaries. The company
holds majority equity interests in 10 biopharmaceutical companies,
three of which are public, and holds minority interests in four
biopharmaceutical companies, two of which are public. The company
also holds a minority equity interest in a public nanotechnology
company. Bioaccelerate's strategy relies on its development network
for research, clinical development and project management to guide
early-stage compounds from the discovery process through to Phase
II/III development where incremental value can be created.
Bioaccelerate Holdings is listed on the Over-The-Counter Bulletin
Board under the symbol "BACL.OB." For more information on
Bioaccelerate, visit the Company's website at
http://www.bioaccelerate.com/. CONTACT: Bioaccelerate Holdings Inc.
Christopher O'Toole Senior Vice President 212-332-4387 Matthew
Haines (Investors) Vice President Noonan Russo 212-845-4235 Emily
Poe (Media) Vice President Noonan Russo 212-845-4266 DATASOURCE:
Bioaccelerate Holdings Inc. CONTACT: Christopher O'Toole, Senior
Vice President of Bioaccelerate Holdings Inc., +1-212-332-4387; or
Matthew Haines (Investors), Vice President of Noonan Russo,
+1-212-845-4235; or Emily Poe (Media), Vice President of Noonan
Russo, +1-212-845-4266 Web site: http://www.bioaccelerate.com/
Copyright